DRRX · Durect Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $447.0K | $321.0K | - | $1.93M | $2.17M | $1.83M | - | $1.74M | $2.08M | $2.05M |
| Cost of Revenue | $7.0K | - | - | $513.0K | $356.0K | $289.0K | - | $312.0K | $359.0K | $388.0K |
| Gross Profit | $440.0K | - | - | $1.41M | $1.81M | $1.54M | - | $1.43M | $1.72M | $1.67M |
| R&D | $1.18M | $1.88M | - | $2.16M | $2.25M | $4.12M | - | $7.20M | $7.95M | $8.59M |
| SG&A | $2.07M | $2.58M | - | $3.22M | $2.97M | $3.14M | - | $3.79M | $3.83M | $4.09M |
| Total Operating Expenses | $3.25M | $4.46M | - | $5.89M | $5.58M | $7.54M | - | $11.30M | $12.13M | $13.08M |
| D&A | - | $69.0K | - | - | - | $51.0K | - | - | - | $44.0K |
| Operating Income | ($2.80M) | ($4.14M) | - | ($3.97M) | ($3.40M) | ($5.72M) | - | ($9.56M) | ($10.05M) | ($11.02M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($2.27M) | ($4.23M) | - | ($4.29M) | ($3.70M) | ($7.64M) | - | ($3.02M) | ($11.18M) | ($11.99M) |
| EPS - Basic | ($0.07) | ($0.13) | - | ($0.14) | ($0.12) | ($0.25) | - | ($0.11) | ($0.46) | ($0.50) |
| EPS - Diluted | ($0.07) | ($0.13) | - | ($0.14) | ($0.12) | ($0.25) | - | ($0.14) | ($0.46) | ($0.52) |
Balance Sheet
| Line item | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.50M | $7.96M | $11.01M | $9.09M | $15.65M | $19.25M | $28.40M | $38.98M | $31.76M | $39.30M |
| Accounts Receivable | $511.0K | $330.0K | $453.0K | $1.02M | $1.01M | $1.02M | $1.26M | $883.0K | $1.30M | $1.40M |
| Inventory | $291.0K | $85.0K | $106.0K | $2.38M | $2.47M | $2.40M | $2.22M | $2.52M | $2.26M | $2.21M |
| Accounts Payable | $393.0K | $313.0K | $309.0K | $498.0K | $394.0K | $782.0K | $1.78M | $1.31M | $980.0K | $2.01M |
| Current Assets | $7.77M | $9.41M | $13.18M | $14.43M | $19.95M | $26.09M | $34.67M | $43.78M | $40.29M | $50.50M |
| Total Assets | $12.48M | $14.36M | $18.35M | $24.07M | $29.85M | $36.22M | $45.19M | $54.73M | $48.66M | $58.35M |
| Current Liabilities | $7.89M | $7.67M | $7.71M | $20.21M | $21.93M | $24.74M | $27.01M | $36.75M | $41.43M | $42.09M |
| Long-term Debt | - | - | - | $10.47M | $12.54M | $14.61M | $16.66M | $18.70M | $20.72M | $21.30M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $3.48M | $5.35M | $9.13M | $1.22M | $5.04M | $8.30M | $14.78M | $14.41M | $5.50M | $15.34M |
| Retained Earnings | ($603.83M) | ($601.56M) | ($597.33M) | ($604.63M) | ($600.35M) | ($596.65M) | ($589.01M) | ($587.57M) | ($584.55M) | ($573.37M) |
Cash Flow
| Line item | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($3.54M) | - | - | - | ($6.77M) | - | - | - | ($9.26M) |
| Investing Cash Flow | - | $496.0K | - | - | - | ($887.0K) | - | - | - | ($4.92M) |
| Financing Cash Flow | - | - | - | - | - | ($1.50M) | - | - | - | $10.00M |
| CapEx | - | $7.0K | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | ($3.55M) | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 98.4% | - | - | 73.4% | 83.6% | 84.2% | - | 82.1% | 82.7% | 81.1% |
| Operating margin | -627.1% | -1289.4% | - | -205.9% | -156.8% | -312.9% | - | -548.0% | -483.0% | -536.6% |
| EBITDA margin | - | -1267.9% | - | - | - | -310.1% | - | - | - | -534.5% |
| Net margin | -506.7% | -1318.4% | - | -222.4% | -170.4% | -418.3% | - | -172.9% | -537.3% | -583.6% |
| Free cash flow margin | - | -1106.2% | - | - | - | - | - | - | - | - |
| FCF / Net income | - | 0.84 | - | - | - | - | - | - | - | - |
| R&D / Revenue | 263.1% | 586.6% | - | 112.3% | 103.5% | 225.5% | - | 412.8% | 381.8% | 418.4% |
| SG&A / Revenue | 462.4% | 802.8% | - | 166.9% | 136.9% | 171.6% | - | 217.3% | 183.9% | 199.4% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -18.1% | -29.5% | - | -17.8% | -12.4% | -21.1% | - | -5.5% | -23.0% | -20.5% |
| Return on equity | -65.0% | -79.1% | - | -352.1% | -73.5% | -92.1% | - | -20.9% | -203.3% | -78.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.98 | 1.23 | 1.71 | 0.71 | 0.91 | 1.05 | 1.28 | 1.19 | 0.97 | 1.20 |
| Quick ratio | 0.95 | 1.22 | 1.70 | 0.60 | 0.80 | 0.96 | 1.20 | 1.12 | 0.92 | 1.15 |
| Cash ratio | 0.82 | 1.04 | 1.43 | 0.45 | 0.71 | 0.78 | 1.05 | 1.06 | 0.77 | 0.93 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | 8.60 | 2.49 | 1.76 | 1.13 | 1.30 | 3.77 | 1.39 |
| Debt / Assets | - | - | - | 0.43 | 0.42 | 0.40 | 0.37 | 0.34 | 0.43 | 0.37 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 3.58 | 2.68 | 2.01 | 19.77 | 5.93 | 4.36 | 3.06 | 3.80 | 8.85 | 3.80 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.04 | 0.02 | - | 0.08 | 0.07 | 0.05 | - | 0.03 | 0.04 | 0.04 |
| Inventory turnover | 0.02 | - | - | 0.22 | 0.14 | 0.12 | - | 0.12 | 0.16 | 0.18 |
| Days sales outstanding | 417d | 375d | - | 192d | 170d | 204d | - | 185d | 229d | 249d |
| Days inventory outstanding | 15174d | - | - | 1691d | 2537d | 3029d | - | 2949d | 2300d | 2080d |
| Days payable outstanding | 20492d | - | - | 354d | 404d | 988d | - | 1537d | 996d | 1887d |
| Cash conversion cycle | -4901d | - | - | 1529d | 2303d | 2245d | - | 1597d | 1532d | 442d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -79.4% | -82.4% | - | 10.5% | 4.3% | -11.1% | - | -85.4% | 0.2% | 7.3% |
| Revenue CAGR (3y) | -40.1% | -44.9% | - | -3.8% | -1.9% | -6.2% | - | -13.4% | -56.8% | -9.5% |
| Revenue CAGR (5y) | -55.6% | -35.0% | - | -29.1% | -11.4% | -15.1% | - | -39.1% | -9.4% | -10.0% |
| Gross profit growth (YoY) | -75.8% | - | - | -1.3% | 5.4% | -7.7% | - | -87.7% | 2.3% | 5.4% |
| Operating income growth (YoY) | 17.7% | 27.6% | - | 58.5% | 66.1% | 48.1% | - | -348.3% | 9.3% | -6.3% |
| Net income growth (YoY) | 38.8% | 44.6% | - | -42.1% | 66.9% | 36.2% | - | -22.0% | 3.2% | -10.6% |
| EPS growth (YoY) | 41.7% | 48.0% | - | 0.0% | 73.9% | 51.9% | - | -1300.0% | -820.0% | -940.0% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -30.9% | -35.5% | -38.2% | -91.6% | -8.4% | -45.9% | -40.8% | -58.7% | -85.0% | -67.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$2.03M totalCollaborative Research And Development And Other Revenue$1.90M · 93.4%
Product$135.0K · 6.6%
Geographic
$2.03M totalEurope$1.59M · 78.4%
Other Foreign Countries$250.0K · 12.3%
US$189.0K · 9.3%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing DURECT CORP against the 5 most active filers in the same SIC group.